Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tensopyn
- Development stage
- Unknown
- Lead developer
- Cipla Medpro
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tensopyn is a combination analgesic tablet indicated for the short-term relief of mild to moderate pain associated with tension, such as headaches, muscle pain, and joint pain. It is a small molecule formulation containing four active pharmaceutical ingredients: paracetamol (acetaminophen), codeine phosphate, caffeine, and doxylamine succinate. Paracetamol acts as an analgesic and antipyretic; codeine phosphate is an opioid analgesic that is metabolized to morphine in the liver to provide pain relief; caffeine serves as an adjuvant to enhance the analgesic effect of paracetamol; and doxylamine succinate is a sedating antihistamine that helps alleviate tension. Marketed by Cipla Medpro in South Africa, Tensopyn is a prescription-only medication (Schedule 2) and is recommended for use for no more than five consecutive days due to the risk of codeine dependence and addiction.
- Brand names
- Tensopyn
02
Targets
ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HRH1 (Histamine H1 Receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on Tensopyn.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tensopyn.